Rhamnazin (5-40 渭M) inhibits proliferation, migration and tube formation of HUVECs induced by VEGF[1].
Rhamnazin (0-20 渭M) attenuates VEGFR-2 tyrosine kinase activity and VEGFR-2 signaling pathway[1].
Rhamnazin (0-40 渭M; 24 h) inhibits the proliferation and VEGFR2 signaling pathway of breast cancer cells[1].
Rhamnazin (200 mg/kg; i.g.; daily for 25 days) inhibits breast cancer growth and angiogenesis in mice[1].
Rhamnazin (5-20 mg/kg; i.p.; once) shows strong antioxidant and anti-inflammatory properties in the rat acute lung injury model[2].
[1]. Yu Y, et al. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy. Biochem Biophys Res Commun. 2015 Mar 20;458(4):913-9.
[2]. Wu G, et al. ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OF RHAMNAZIN ON LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY AND INFLAMMATION IN RATS. Afr J Tradit Complement Altern Med. 2017 Jun 5;14(4):201-212.